System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Mehmet Artac is an expert in Oncology at Necmettin Erbakan University (Turkey). As of October 2026, ScienceLeadR ranks Mehmet Artac in the top 1% of experts worldwide for Lung Neoplasms, Thoracic Neoplasms and Carcinoma. Mehmet Artac has authored 234 publications, the most recent in 2026, and is an investigator in 19 clinical trials, 5 of them ongoing. SLR score: 1,113 (community average: 125). How the SLR is computed.

LeadR Profile

Mehmet Artac Necmettin Erbakan University Turkey
1 113 ScienceLeadR Reputation 1113

Unlock

Register Login
Network Map

Oncology

Subspecialties: Pharmacy - Immunology - Pulmonology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Short Biography

Dr. Mehmet Artac is a Professor of Medical Oncology and director of Medical Oncology Department at Necmettin Erbakan University Meram School of Medicine in Konya, Turkey. He is certified by both the European Society of Medical Oncology (ESMO) and Turkish Medical Oncology Society in Medical Oncology. Dr.Artac’s primary research focus is the oversight of clinical trials of novel therapeutic agents and translational research on patients with breast, lung and colon cancer. He is actively involved in clinical trials. Dr.Artac has received numerous awards, including the American Society of Clinical Oncology (ASCO) International Education and Development Award (IDEA) (2006), and Turkish Medical Oncology Society Research Award (2006). He belongs to numerous professional organizations including the ASCO and ESMO. He has authored over 70 articles in peer-reviewed journals. Dr.Artac received his MD (1996) at the Ege University School of Medicine in Izmir. He trained in oncology at the Akdeniz University School of Medicine in Antalya.

Organizations

Career arc: 2006 - 2026
Source: PubMed

Necmettin Erbakan Üniversitesi Meram Tıp Fakültesi Hastanesi

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 234

Citations

Citations: 7 913 1st author: 27 Last author: 85 Unique author: 0

Main journals

J Clin Oncol 19
J Oncol Pharm Pract 15
Ann Oncol 12
J Cancer Res Ther 10
J Gastrointest Cancer 9

Best Journals

J Clin Oncol 10
Ann Oncol 9
N Engl J Med 6

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
FGFR 1-3 Alteration Frequency in Muscle-Invasive Urothelial Bladder Cancer and Its Effect on Prognosis.
PMID 42942557 — urinary bladder, urinary bladder neoplasms, muscles, neoplasms, prognosis		Medicina (Kaunas)20260
Integrated Inflammatory and Nutritional Biomarkers in Metastatic Renal Cell Carcinoma Treated with Second- or Later-Line Nivolumab: A Retrospective Cohort Study.
PMID 42654418 — cells, research design, multiple chronic conditions, cohort studies, carcinoma, renal cell, biomarkers, nivolumab, therapeutics		Medicina (Kaunas)20260
First-Line Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data from Turkey.
PMID 42590101 — carcinoma, hepatocellular, safety, immunotherapy, viruses, therapeutics, hepatitis		J Clin Med20260
Prognostic Impact of the Systemic Immune-Inflammation Index According to Concurrent Chemotherapy Backbone in Stage III Non-Small Cell Lung Cancer.
PMID 42505209 — cells, lung, paclitaxel, neoplasms, carcinoma, non-small-cell lung, drug therapy, lung neoplasms, chemoradiotherapy, small cell lung carcinoma, carboplatin, chemotherapy		Curr Oncol20260
Mismatch repair deficiency or microsatellite instability in locally advanced rectal cancer patients treated with total neoadjuvant therapy.
PMID 42407299 — dna mismatch repair, microsatellite repeats, neoplasms, neoadjuvant therapy, rectal neoplasms, therapeutics, microsatellite instability		Eur J Cancer20260

Clinical Studies 19

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1 Study Director: 2

By phase:

Phase 3 9
N/A 8
Phase 2 2

By status:

Completed 10
Recruiting 4
Active not recruiting 3
Not yet recruiting 1
Unknown 1

By type:

Interventional 14
Observational 5

By Monocentric/Multicentric:

monocentric 8
multicentric2to4 0
multicentric5to9 2
multicentricup10 9

Main Topics

Ongoing Clinical Trials

5 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Large Granular Lymphocytes in mNSCLC Treated With Nivolumab
NCT07363811 — cells, lung, blood, lymphocytes, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, cytoplasm, small cell lung carcinoma, nivolumab, carcinoma		N/ARecruiting2025
ADAR1 Expression Level in Rectal Cancer
NCT07108348 — adenosine deaminase, dna mismatch repair, immunohistochemistry, polymerase chain reaction, neoplasms, adenocarcinoma, colon, biopsy, adenosine, rectum, enzymes, neoadjuvant therapy, rectal neoplasms, therapeutics, tissues, real-time polymerase chain reaction, colonic neoplasms, rna, sensitivity and specificity		N/ARecruiting2025
The Impact of Probiotic on Survival and Treatment Response in Metastatic Non small Cell Lung Cancer Patients
NCT06428422 — cells, lung, bifidobacterium animalis, neoplasms, carcinoma, non-small-cell lung, immunotherapy, lung neoplasms, small cell lung carcinoma, probiotics, bifidobacterium, nivolumab, therapeutics, microbiota, carcinoma		N/ARecruiting2024
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited stage Small Cell Lung Cancer (LS SCLC)
NCT06095583 — injections, cells, lung, neoplasms, disease progression, multiple chronic conditions, lung neoplasms, chemoradiotherapy, small cell lung carcinoma, antibodies, monoclonal, therapeutics, carcinoma		Phase 3Recruiting2023
Effects of Ketogenic Diet in Overweight and Obese Women With Breast Cancer
NCT05234502 — exercise, research design, quality of life, breast neoplasms, neoplasms, drug therapy, diet, polyneuropathies, breast, diet, ketogenic, neoadjuvant therapy, nutritional status, therapeutics, overweight, diet, healthy, chemotherapy, female, women		N/ANot yet recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS